396 related articles for article (PubMed ID: 35245568)
21. Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy.
Xu W; Liu W; Yang J; Lu J; Zhang H; Ye D
Immunol Rev; 2024 Jan; 321(1):181-198. PubMed ID: 37403660
[TBL] [Abstract][Full Text] [Related]
22. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
[TBL] [Abstract][Full Text] [Related]
23. Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy.
Fu S; Li G; Zang W; Zhou X; Shi K; Zhai Y
Acta Pharm Sin B; 2022 Jan; 12(1):92-106. PubMed ID: 35127374
[TBL] [Abstract][Full Text] [Related]
24. Self-Assembly Dual-Responsive NO Donor Nanoparticles for Effective Cancer Therapy.
Gu G; Chen C; Zhang S; Yin B; Wang J
ACS Appl Mater Interfaces; 2021 Nov; 13(43):50682-50694. PubMed ID: 34668695
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint-targeted drug conjugates: A promising tool for remodeling tumor immune microenvironment.
Choi J; Jang H; Choi J; Choi Y; Yang Y; Shim MK; Kim SH
J Control Release; 2023 Jul; 359():85-96. PubMed ID: 37230294
[TBL] [Abstract][Full Text] [Related]
26. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
[TBL] [Abstract][Full Text] [Related]
27. Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers.
Shi F; Huang X; Hong Z; Lu N; Huang X; Liu L; Liang T; Bai X
Cancer Lett; 2023 May; 562():216167. PubMed ID: 37031916
[TBL] [Abstract][Full Text] [Related]
28. Biomimetic nanoparticles for tumor immunotherapy.
Yu H; Wu M; Chen S; Song M; Yue Y
Front Bioeng Biotechnol; 2022; 10():989881. PubMed ID: 36440446
[TBL] [Abstract][Full Text] [Related]
29. Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery.
Wang Z; Chen J; Little N; Lu J
Acta Biomater; 2020 Jul; 111():20-28. PubMed ID: 32454086
[TBL] [Abstract][Full Text] [Related]
30. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
[TBL] [Abstract][Full Text] [Related]
31. Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy.
Yang S; Sun IC; Hwang HS; Shim MK; Yoon HY; Kim K
J Mater Chem B; 2021 May; 9(19):3983-4001. PubMed ID: 33909000
[TBL] [Abstract][Full Text] [Related]
32. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
33. Tailoring carrier-free nanocombo of small-molecule prodrug for combinational cancer therapy.
Li H; Zang W; Mi Z; Li J; Wang L; Xie D; Zhao L; Wang D
J Control Release; 2022 Dec; 352():256-275. PubMed ID: 36272660
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
35. Camptothecin-based prodrug nanomedicines for cancer therapy.
Zhang R; Yu J; Guo Z; Jiang H; Wang C
Nanoscale; 2023 Nov; 15(44):17658-17697. PubMed ID: 37909755
[TBL] [Abstract][Full Text] [Related]
36. Two-Stage SN38 Release from a Core-Shell Nanoparticle Enhances Tumor Deposition and Antitumor Efficacy for Synergistic Combination with Immune Checkpoint Blockade.
Jiang X; Lee M; Xia J; Luo T; Liu J; Rodriguez M; Lin W
ACS Nano; 2022 Dec; 16(12):21417-21430. PubMed ID: 36382721
[TBL] [Abstract][Full Text] [Related]
37. An "AND" Logic-Gated Prodrug Micelle Locally Stimulates Antitumor Immunity.
Chen M; Wang C; Wang X; Tu Z; Ding Z; Liu Z
Adv Mater; 2024 Feb; 36(6):e2307818. PubMed ID: 37935201
[TBL] [Abstract][Full Text] [Related]
38. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.
Zhou F; Feng B; Yu H; Wang D; Wang T; Ma Y; Wang S; Li Y
Adv Mater; 2019 Apr; 31(14):e1805888. PubMed ID: 30762908
[TBL] [Abstract][Full Text] [Related]
39. Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy.
Guo J; Zou Y; Huang L
Small Methods; 2023 May; 7(5):e2201307. PubMed ID: 36604976
[TBL] [Abstract][Full Text] [Related]
40. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
